On May 27, 2022, RS&A, LLC ("RSA") was acquired by Sheridan Capital Partners ("Sheridan").
The Healthcare Investment Banking practice of Kroll served as an exclusive sell-side M&A advisor to RS&A, LLC in connection with the transaction.
RSA is a North Carolina-based medical device independent service provider for radiotherapy equipment, most notably external beam linear accelerators (LINACs). Since 1995, RSA has supported the oncology community through equipment life cycle management, maintenance, parts, and removals/installations. RSA built its business by delivering a responsive and professional service to the oncology industry, enabling its clients to deliver quality patient care. Its client base includes hospitals, medical centers, private cancer centers, universities, veterinary clinics, urology clinics, and GPO/asset management groups across North, Central, and South America. Woods Oviatt Gilman, LLP served as legal counsel to RSA in connection with the transaction.
About Sheridan Capital Partners
Sheridan is a Chicago-based health care private equity firm that focuses on lower middle market buyouts and growth equity in the U.S. and Canada. Sheridan partners with companies in the verticals of providers and provider services, health care IT and outsourced services, and medical products, bringing strategic resources to accelerate growth, build enduring value, and achieve strong results. McGuireWoods, LLP served as legal counsel to Sheridan in connection with the transaction.